# Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer

## TL;DR

This review explores how long non-coding RNAs (lncRNAs) could help monitor and treat breast cancer by acting as biomarkers and therapeutic targets.

## Contribution

The paper highlights the novel potential of lncRNAs as diagnostic, prognostic, and therapeutic tools in breast cancer.

## Key findings

- LncRNAs are involved in key biological processes relevant to breast cancer.
- Tumor-specific lncRNAs may improve breast cancer clinical practices.
- LncRNAs are proposed as potential therapeutic targets.

## Abstract

Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/or HER2, as well as the degree of proliferative activity. Recent work has focused on improving our knowledge on the molecular mechanisms that underlie this complex disease. Most of the human genome is transcribed into RNAs that do not encode proteins. These noncoding RNAs may act as mediators in the regulation of gene expression. Based on their size and function, noncoding RNAs are classified into small noncoding RNAs (sncRNAs) and long noncoding RNAs (lncRNAs). LncRNAs have been found to play key roles in relevant biological processes, including breast cancer. As such, lncRNAs have been proposed as diagnostic and prognostic biomarkers, as predictive biomarkers and as putative therapeutic targets.

In this review, we discuss the potential application of lncRNAs for the monitoring and treatment of breast cancer. We conclude that lncRNAs play important roles in the pathophysiology of this disease and may serve as putative therapeutic targets. As such, tumor-specific lncRNAs may be instrumental for improving current breast cancer clinical practices.